0.00Open0.20Pre Close0 Volume1 Open Interest3.00Strike Price0.00Turnover146.13%IV83.91%PremiumFeb 21, 2025Expiry Date0.00Intrinsic Value100Multiplier85DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.3425Delta0.2995Gamma8.70Leverage Ratio-0.0027Theta0.0009Rho2.98Eff Leverage0.0031Vega
Brainstorm Cell Therapeutics Stock Discussion
PR Newswire· 3 mins ago
Memorandum of Understanding has been signed
NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly o...
28/10/2024 - 18:00
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenera...
5 MINUTES AGO, 6:00 AM EDT
VIA PR NEWSWIRE
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
No comment yet